EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Serum Type I Interferon Score for Prediction of Clinically Meaningful Disease Progression in Limited Cutaneous Systemic Sclerosis

Stefano Di Donato iD, Rebecca Ross iD, Ranjitha Karanth, Vishal Kakkar, Enrico De Lorenzis iD, Lesley-Anne Bissell, Kristina Clark, Philip Yee, Christopher P Denton iD, Francesco Del Galdo iD

Arthritis & Rheumatology · 2025-07 · 77 (7) · 929-941

DOI: 10.1002/art.43120 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Arthritis & Rheumatology, online erschienen am 03.03.2025. Verfasst von Stefano Di Donato und 9 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds Biomedical Research Centre, National Institute for Health Re…. Hauptthemen laut MEDLINE: Interferon Type I, Scleroderma, Systemic. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Leeds Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess the value of serum type I interferon (IFN) score in predicting clinically meaningful progression in limited cutaneous systemic sclerosis (lcSSc) using a novel composite endpoint adopted from the MINIMISE clinical trial.

Methods

A retrospective, longitudinal lcSSc cohort was identified within a national, multicenter observational cohort. The MINIMISE trial combined Morbi‐mortality endpoint was used as the clinical outcome for a time to clinical worsening (TTCW) design. The IFN score was calculated from the serum concentration of chemokine C‐C motif ligand (CCL) 2, CCL8, CCL19, C‐X‐C motif chemokine ligand (CXCL) 9, CXCL10, and CXCL11 on patients and age‐ and sex‐matched healthy controls (HCs). A “high” IFN score was defined as 2 SDs above the HC mean. The association of the IFN score with TTCW was assessed using Cox proportional hazard regressions and Kaplan‐Meier curves. The potential improvement in risk stratification when combining IFN score with lcSSc clinical features was explored.

Results

A total of 149 patients were included in the analysis: 67 “high” IFN and 82 “low.” High IFN patients presented a shorter TTCW (74.7 months [95% confidence interval (CI) 70.1–79.3] vs 110.6 months [95% CI 107.2–114.0]; P < 0.001) and met the endpoint in higher proportion compared with low IFN (55% vs 12%; P < 0.001). A high IFN score conferred hazard ratio (HR) 5.5 (95% CI 2.7–11.3) for TTCW compared with low IFN, and IFN score as a continuous variable conferred HR 2.38 (95% CI 1.4–4.0) for TTCW independently of clinical variables. Pulmonary arterial hypertension, interstitial lung disease, digital ulcers, and modified Rodnan skin score were associated with TTCW. An exploratory analysis showed that these clinical features improve risk stratification over time in combination with IFN score.

Conclusion

Serum assessment of type I IFN activity is a valuable predictor of clinically meaningful outcomes in lcSSc. The combination of serum IFN score with sentinel clinical features can improve stratification strategies in clinical trials and patient management. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interferon Type IScleroderma, SystemicHumansFemaleMaleDisease ProgressionMiddle AgedRetrospective StudiesAdultAgedLongitudinal StudiesProportional Hazards ModelsChemokine CXCL10

Substanzen

Interferon Type IChemokine CXCL10

Autor:innen und Institutionen

  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds Biomedical Research Centre, National Institute for Health Research, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom.
  • Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • University College London, London, United Kingdom.

ORCID-Profile: Stefano Di Donato, Rebecca Ross, Enrico De Lorenzis, Christopher P Denton, Francesco Del Galdo

Förderung

  • Leeds Biomedical Research Centre

Zitieren

APA

Di Donato, S., Ross, R., Karanth, R., Kakkar, V., De Lorenzis, E., Bissell, L. A., Clark, K., Yee, P., Denton, C. P., & Del Galdo, F. (2025). Serum Type I Interferon Score for Prediction of Clinically Meaningful Disease Progression in Limited Cutaneous Systemic Sclerosis. Arthritis & Rheumatology, 77(7), 929-941. https://doi.org/10.1002/art.43120

Vancouver

Di Donato S, Ross R, Karanth R, Kakkar V, De Lorenzis E, Bissell LA, et al. Serum Type I Interferon Score for Prediction of Clinically Meaningful Disease Progression in Limited Cutaneous Systemic Sclerosis. Arthritis & Rheumatology. 2025;77(7):929-941. doi:10.1002/art.43120

BibTeX
@article{DiDonato2025,
  author = {Di Donato, Stefano and Ross, Rebecca and Karanth, Ranjitha and Kakkar, Vishal and De Lorenzis, Enrico and Bissell, Lesley-Anne and Clark, Kristina and Yee, Philip and Denton, Christopher P and Del Galdo, Francesco},
  title = {Serum Type I Interferon Score for Prediction of Clinically Meaningful Disease Progression in Limited Cutaneous Systemic Sclerosis},
  journal = {Arthritis & Rheumatology},
  year = {2025},
  volume = {77},
  number = {7},
  pages = {929--941},
  doi = {10.1002/art.43120}
}
Kostenlos starten →